On the surface, Mylan's
On the revenue side, last year's number included the sale to Forest Labs
Interestingly, revenue from its branded-drug division, Dey, rose by 20% year over year. Mylan was going to sell Dey but didn't, probably because it couldn't find a buyer willing to pay enough. Looks like that was a pretty smart move.
The net loss for the quarter was attributable to a $121 million charge to settle a Department of Justice investigation over calculations of Medicaid drug rebates. The previously announced settlement isn't a great thing, but it's not the only drugmaker to have been stung by the DOJ, and things could have been a lot worse: Eli Lilly
The benefit from Mylan's larger size after acquiring Merck KGaA's generic-drug business is starting to show. The company may be at a slight disadvantage since it isn't as big as rivals Teva Pharmaceuticals